title: Nitric oxide mediates increased prostaglandin E production by oocyte-cumulus complexes in the non-insulin-dependent diabetic rat.
abstract: Previous work described an increase in prostaglandin E (PGE) production by oocyte-cumulus complexes (OVA) obtained from non-insulin-dependent diabetic rats. More recently, it has been found that in control OVA nitric oxide (NO) mediates hCG-induced PGE secretion. To determine whether increases in PGE secretion by diabetic OVA are mediated by NO, the present study has evaluated the secretion of PGE by diabetic OVA, cultured in the absence or presence of hCG, NO donors (sodium nitroprusside (NP) and 3-morpholino-sydnonimine-hydrochloride (SIN-1)), and a NO synthase inhibitor (N(G)monomethyl-L-arginine; L-NMMA). hCG, NP and SIN-1 increased PGE secretion by diabetic OVA. L-NMMA did not modify basal secretion of PGE by control OVA but lowered PGE production in diabetic OVA to control values. L-NMMA prevented the hCG-induced PGE accumulation in control and diabetic OVA, and the quantities of PGE produced were similar to those of control OVA but lower than in diabetic OVA incubated in the absence of hCG. The effect of L-NMMA seems to be specific since N(G)monomethyl-D-arginine had no effect. NO synthase activity was higher in diabetic ovaries than in controls. The present results suggest that NO mediates the increased PGE production by diabetic OVA, probably a result of overproduction of NO.
authors.affiliation: Centro de Estudios Farmacológicos y Botánicos, Consejo Nacional de Investigaciones Cientificas y Técnicas, Buenos Aires, Argentina. A.JAWERBAUM@ABACONET.COM.AR
authors.forename: A
authors.initials: A
authors.lastname: Jawerbaum
authors.forename: E T
authors.initials: ET
authors.lastname: Gonzalez
authors.forename: V
authors.initials: V
authors.lastname: Novaro
authors.forename: A
authors.initials: A
authors.lastname: Faletti
authors.forename: M A
authors.initials: MA
authors.lastname: Gimeno
mesh_terms: D000818:Animals; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D052250:Nitric Oxide Synthase Type III; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism*; D011458:Prostaglandins E / Q000096:biosynthesis*; D051381:Rats; D017208:Rats, Wistar; D019323:omega-N-Methylarginine / Q000494:pharmacology
chemical_list: D006063:Chorionic Gonadotropin; D004791:Enzyme Inhibitors; D011458:Prostaglandins E; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; C496316:Nos3 protein, rat